• VIDAS® Acute Coronary Syndrome (ACS) panel

VIDAS® Acute Coronary Syndrome panel

Accurate diagnosis of myocardial infarction

VIDAS® Troponin I Ultra, VIDAS® CK-MB and VIDAS® Myoglobin* are automated quantitative assays for the assessment of myocardial damage.

  • High clinical sensitivity and specificity for the diagnosis of acute myocardial infarction and risk stratification (Troponin I Ultra)
  • 3 complementary markers
  • Reliable platform for rapid response laboratories
Add to my selection

Do you need more information

The VIDAS® Acute Coronary Syndrome (ACS) panel offers three complementary tests for the assessment of myocardial injury1, 2. In combination with clinical examination and an electrocardiogram, they enable timely and accurate evaluation of patients for optimal care. Performed on the instruments of the VIDAS® family, these assays are particularly suitable for emergency testing.

Complementary markers for the diagnosis of acute myocardial infarction (AMI)

Cardiac Troponin I (cTnI) is the preferred biomarker of cardiac necrosis due to its specificity for myocardial tissue damage2. A rapid increase of cTnl levels (within 3 to 6 hours after the onset of chest pain) and the fact they remain elevated for 4 to 7 days5 give cTnI high diagnostic value for myocardial infarction.

The protein concentration of the MB isoenzyme of human creatine kinase (CK-MB) is recommended for the diagnosis of myocardial infarction when cardiac troponin assays are not available5. CK-MB also increases rapidly after infarction. Due to its shorter half-life, it can be used as a marker for re-infarction.

Myoglobin is one of the first markers of myocardial damage to be measured after the onset of myocardial infarction. For patients presenting within 6 hours of the onset of symptoms, it may be considered in addition to cardiac troponin for early rule-out5.

Temporal profile of cardiac necrosis markers after acute myocardial infarction
(adapted from [6]).

 

Clinical sensitivity and specificity of VIDAS® Troponin I Ultra

  • High clinical sensitivity for the diagnosis of myocardial infarction3 (cf. table below)
  • Enables significant short-term risk stratification for early and improved patient triage and management3
  • Sensitive test for the identification of ACS patients with poor clinical outcomes4

Clinical performance of VIDAS® Troponin I Ultra for patients presenting with symptoms suggestive of ACS*:

Clinical Performance (using the 99th percentile cut-off: 0.01µg/L)3
 

Clinical Performance (using the 10%CV cut-off: 0.11µg/L)7
 

VIDAS® solution benefits

  • Reliable and easy-to-use instruments with random access and small foot-print. Well adapted to rapid response laboratories.
  • Factory-calibrated, single-dose tests which reduce the need for additional controls**.
  • Short time to result: VIDAS Troponin I Ultra result available in only 20 minutes; comparable assay times for VIDAS CK-MB and Myoglobin.
  • Reagents can be used immediately after removal from the refrigerator.
  • VIDAS NT-proBNP2 available on the same platform.

* Please consult our local subsidiary or representatives for the availability of these products in your country.
** Depending on local guidelines.

 

 

References:

  1. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32: 2999-3054.
  2. Thygesen K, Alpert JS, Jaffe AS, et al., the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567
  3. Apple FS, Smith SW, Pearce LA, et al. Use of the bioMérieux VIDAS® troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms of acute coronary syndrome. Clin Chem Acta 2008;390:72-75.
  4. Venge, P and Lindahl, B. Cardiac Troponin Assay Classification by Both Clinical and Analytical Performance Characteristics: A Study in Outcome Prediction. Clin Chem 2013;59:976-81.
  5. Morrow, DA, Cannon CP, Jesse JL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007; 115: 356-75.
  6. Wu AH, Apple FS, Gibler WB et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem. 1999; 45: 1104-1121.
  7.  Package insert, VIDAS Troponin I Ultra (TNIU), CE-mark. August 2010.
  VIDAS® Troponin I Ultra VIDAS® CK-MB VIDAS® Myoglobin
Reference 30448 30421 30446
Kit size 60 tests 30 tests 30 tests
Sample type Serum, plasma (heparin) Serum, plasma (heparin, EDTA) Serum, plasma (heparin)
Sample volume 200 µL 250 µL 150 µL
Calibration / Control Frequency 28 days 14 days 14 days
Time to result 20 minutes 30 minutes 17 minutes

 

Find more technical details on www.myvidas.com.

Consult your local bioMérieux representative for product availability in your country.

RELATED PUBLICATIONS

Troponin I Ultra

  1. Apple FS, Smith SW, Pearce LA, et al. Use of the bioMérieux VIDAS® troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms of acute coronary syndrome. Clin Chem Acta 2008;390:72-75.
  2. Venge, P and Lindahl, B. Cardiac Troponin Assay Classification by Both Clinical and Analytical Performance Characteristics: A Study in Outcome Prediction. Clin Chem 2013;59:976-81.

CK-MB

  1. Poirey S, Polge A, Bertinchant JP et al. CK-MB mass test in ischemic myocardial injury. Comparison of two tests: BioMerieux VIDAS and Sanofi Access immunoassays. J Clin Lab Anal 2000;14:43-47.

Myoglobin

  1. Le Moigne F, Beauvieux MC, Derache P and Darmon YM. Determination of myoglobin : comparative evaluation of the new automated VIDAS assay with two other immunoassays. Clin Biochem 2002;35: 255-262.

GUIDELINES

  1. Thygesen K, Alpert JS, Jaffe AS, et al., the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infraction.Eur Heart J.2012;33:2551-2567.
  2. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32: 2999-3054.
  3. Thygesen K, Mair J, Katus H, et al. Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31:2197-204.
  4. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2012;60:645-681
  5. Morrow DA, Cannon, CP, Jesse, RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007; 115: e356-75.

USEFUL LINKS

 

Find more scientific and educational resources on www.myvidas.com

Pioneering Diagnostics